Maria Rosa Bani

List of Publications by Year
in descending order

40 papers	1,860 citations	257450 24 h-index	276875 41 g-index
42 all docs	42 docs citations	42 times ranked	2664 citing authors

#	Article	IF	Citations
1	Telomere elongation by hnRNP A1 and a derivative that interacts with telomeric repeats and telomerase. Nature Genetics, 1998, 19, 199-202.	21.4	267
2	The A1 and A1B proteins of heterogeneous nuclear ribonucleoparticles modulate 5' splice site selection in vivo.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 6924-6928.	7.1	189
3	Retroviral integration within the Fli-2 locus results in inactivation of the erythroid transcription factor NF-E2 in Friend erythroleukemias: evidence that NF-E2 is essential for globin expression.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 8398-8402.	7.1	129
4	Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations. Cancer Research, 2014, 74, 6980-6990.	0.9	110
5	Paclitaxel Enhances Therapeutic Efficacy of the F8-IL2 Immunocytokine to EDA-Fibronectinâ€“Positive Metastatic Human Melanoma Xenografts. Cancer Research, 2012, 72, 1814-1824.	0.9	86
6	Effect of Interleukin-1-beta on Metastasis Formation in Different Tumor Systems. Journal of the National Cancer Institute, 1991, 83, 119-123.	6.3	84
7	Retroviral insertions downstream of the heterogeneous nuclear ribonucleoprotein A1 gene in erythroleukemia cells: evidence that A1 is not essential for cell growth.. Molecular and Cellular Biology, 1992, 12, 4449-4455.	2.3	82
8	â€˜Proteolytic switchingâ€™: opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression. British Journal of Cancer, 1999, 80, 504-512.	6.4	59
9	Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics, 2008, 9, 201.	2.8	56
10	Soluble stromaâ€•related biomarkers of pancreaticÂcancer. EMBO Molecular Medicine, 2018, 10, .	6.9	56
11	The Vascular Targeting Property of Paclitaxel Is Enhanced by SU6668, a Receptor Tyrosine Kinase Inhibitor, Causing Apoptosis of Endothelial Cells and Inhibition of Angiogenesis. Clinical Cancer Research, 2006, 12, 1839-1849.	7.0	54
12	p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. Oncogene, 2001, 20, 7293-7300.	5.9	51
13	Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications. Oncogene, 2000, 19, 395-402.	5.9	50
14	Targeting melanoma stem cells with the Vitamin E derivative Î´-tocotrienol. Scientific Reports, 2018, 8, 587.	3.3	46
15	Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Molecular Cancer Therapeutics, 2004, 3, 111-21.	4.1	46
16	Thrombospondinâ€•1 is part of a Slugâ€•independent motility and metastatic program in cutaneous melanoma, in association with <scp>VEGFR</scp>â€•1 and <scp>FGF</scp>â€•2. Pigment Cell and Melanoma Research, 2015, 28, 73-81.	3.3	45
17	Posttranscriptional Stimulation of Endothelial Cell Matrix Metalloproteinases 2 and 1 by Endothelioma Cells. Experimental Cell Research, 2000, 258, 384-394.	2.6	43
18	Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumorâ€™s proangiogenic microenvironment. Cellular and Molecular Life Sciences, 2012, 69, 1167-1178.	5.4	40

#	Article	IF	Citations
19	Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle. Oncotarget, 2015, 6, 3043-3054.	1.8	38
20	Phenotypic and functional characteristics of tumour-derived microvascular endothelial cells. Clinical and Experimental Metastasis, 1999, 17, 655-662.	3.3	35
21	Inhibition of matrix metalloproteinases by overâ€expression of tissue inhibitor of metalloproteinaseâ€2 inhibits the growth of experimental hemangiomas. International Journal of Cancer, 2001, 91, 241-247.	5.1	29
22	Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Molecular Cancer Therapeutics, 2005, 4, 715-725.	4.1	27
23	VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status. Journal of Hematology and Oncology, 2021, 14, 186.	17.0	27
24	The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma. Oncogene, 2000, 19, 1419-1427.	5.9	26
25	Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression. British Journal of Dermatology, 2011, 164, 1061-1070.	1.5	25
26	Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists. Angiogenesis, 2017, 20, 233-241.	7.2	22
27	Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype. Clinical and Experimental Metastasis, 2010, 27, 43-53.	3.3	18
28	Dual Targeting of Tumor and Endothelial Cells by Gonadotropin-Releasing Hormone Agonists to Reduce Melanoma Angiogenesis. Endocrinology, 2010, 151, 4643-4653.	2.8	15
29	PGC1Î±/Î² Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer. Cancer Research, 2022, 82, 1423-1434.	0.9	14
30	Blood coagulation changes in nude mice bearing human colon carcinomas. International Journal of Cancer, 1992, 50, 75-79.	5.1	13
31	Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2. Oncotarget, 2015, 6, 28389-28400.	1.8	13
32	Tumorâ€™host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds. Cancer and Metastasis Reviews, 2007, 26, 481-488.	5.9	12
33	The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases. Molecular Cancer Therapeutics, 2022, 21, 555-567.	4.1	11
34	Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts. Connective Tissue Research, 2015, 56, 355-363.	2.3	10
35	Tumor progression and metastatic dissemination in ovarian cancer after doseâ€dense or conventional paclitaxel and cisplatin plus bevacizumab. International Journal of Cancer, 2018, 143, 2187-2199.	5.1	8
36	Establishment of patient-derived tumor xenograft models of mucinous ovarian cancer. American Journal of Cancer Research, 2020, 10, 572-580.	1.4	6

#	Article	IF	Citations
37	Human Immunodeficiency Virus-1 (HIV-1)-Tat Protein Promotes Migration of Acquired Immunodeficiency Syndromeâ€"Related Lymphoma Cells and Enhances Their Adhesion to Endothelial Cells. Blood, 1999, 94, 1747-1754.	1.4	5
38	Modeling Cytostatic and Cytotoxic Responses to New Treatment Regimens for Ovarian Cancer. Cancer Research, 2017, 77, 6759-6769.	0.9	4
39	Invasion and Metastasis. , 2004, , 443-461.		4
40	Anticancer Therapy with Angiogenesis Inhibitors. Tumori, 2001, 87, 14-16.	1.1	1